Dabrafenib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-DABRAFENIB |
|---|---|
| Type | Drug |
| Aliases | TafinlarДабрафеніб |
| Status | pending_clinical_signoff |
| Diseases | DIS-MELANOMA DIS-NSCLC DIS-THYROID-ANAPLASTIC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Drug Facts
| Class | BRAF inhibitor |
|---|---|
| Mechanism | Selective BRAF V600E/K inhibitor. Always combined with trametinib (MEKi) to prevent paradoxical RAF activation in BRAF-WT cells and improve efficacy. |
| Typical dosing | 150 mg PO BID + trametinib 2 mg PO daily. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
BRAF V600E NSCLC 1L+. Pyrexia management: hold + restart at lower dose; antipyretics. Combination essential.
Used By
Regimens
REG-DAB-TRAM-ATC- Dabrafenib + trametinib (anaplastic thyroid carcinoma, BRAF V600E)REG-DABRAFENIB-TRAMETINIB-NSCLC- Dabrafenib + trametinib (BRAF V600E+ NSCLC)